Tags

Type your tag names separated by a space and hit enter

Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
J Drugs Dermatol. 2015 Jan; 14(1):33-40.JD

Abstract

Rosacea is a chronic inflammatory disease with a complex pathophysiology that manifests with central facial redness with or without papulopustular lesions. Often, patients with rosacea present with a constellation of signs and symptoms; for best results, the treatment plan should take into account all symptoms manifesting in the individual patient. The first available pharmacologic treatment to address the redness associated with rosacea is topical brimonidine. In the United States, brimonidine topical gel 0.33% is indicated for persistent facial erythema of rosacea; approval was based on clinically significant efficacy and good safety data from large-scale clinical trials. Use of brimonidine in routine clinical practice has yielded new insights that elaborate on the findings from clinical trials. For example, real-world use has shown that a percentage of patients (in our experience, approximately 10 to 20%) treated with brimonidine experience a worsening of erythema that has been called "rebound." Our routine use of this agent for >1 year has yielded strategies to set patient expectations, optimize treatment initiation, and minimize potential problems; this article details those strategies. Because we believe that the term "rebound" has been used to describe several physiologically distinct events, we have also proposed more specific terminology for such events.

Authors

Tanghetti EA
No affiliation info available
Jackson JM
No affiliation info available
Belasco KT
No affiliation info available
Friedrichs A
No affiliation info available
Hougier F
No affiliation info available
Johnson SM
No affiliation info available
Kerdel FA
No affiliation info available
Palceski D
No affiliation info available
Hong HC
No affiliation info available
Hinek A
No affiliation info available
Cadena MJ
No affiliation info available

MeSH

Administration, CutaneousAdrenergic alpha-2 Receptor AgonistsBrimonidine TartrateDermatologic AgentsGelsHumansQuinoxalinesRosaceaTreatment Outcome

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25607906

Citation

Tanghetti, Emil A., et al. "Optimizing the Use of Topical Brimonidine in Rosacea Management: Panel Recommendations." Journal of Drugs in Dermatology : JDD, vol. 14, no. 1, 2015, pp. 33-40.
Tanghetti EA, Jackson JM, Belasco KT, et al. Optimizing the use of topical brimonidine in rosacea management: panel recommendations. J Drugs Dermatol. 2015;14(1):33-40.
Tanghetti, E. A., Jackson, J. M., Belasco, K. T., Friedrichs, A., Hougier, F., Johnson, S. M., Kerdel, F. A., Palceski, D., Hong, H. C., Hinek, A., & Cadena, M. J. (2015). Optimizing the use of topical brimonidine in rosacea management: panel recommendations. Journal of Drugs in Dermatology : JDD, 14(1), 33-40.
Tanghetti EA, et al. Optimizing the Use of Topical Brimonidine in Rosacea Management: Panel Recommendations. J Drugs Dermatol. 2015;14(1):33-40. PubMed PMID: 25607906.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Optimizing the use of topical brimonidine in rosacea management: panel recommendations. AU - Tanghetti,Emil A, AU - Jackson,J Mark, AU - Belasco,Kevin Tate, AU - Friedrichs,Amanda, AU - Hougier,Firas, AU - Johnson,Sandra Marchese, AU - Kerdel,Francisco A, AU - Palceski,Dimitry, AU - Hong,H Chih-Ho, AU - Hinek,Anna, AU - Cadena,Maria Jose Rueda, PY - 2015/1/22/entrez PY - 2015/1/22/pubmed PY - 2015/9/29/medline SP - 33 EP - 40 JF - Journal of drugs in dermatology : JDD JO - J Drugs Dermatol VL - 14 IS - 1 N2 - Rosacea is a chronic inflammatory disease with a complex pathophysiology that manifests with central facial redness with or without papulopustular lesions. Often, patients with rosacea present with a constellation of signs and symptoms; for best results, the treatment plan should take into account all symptoms manifesting in the individual patient. The first available pharmacologic treatment to address the redness associated with rosacea is topical brimonidine. In the United States, brimonidine topical gel 0.33% is indicated for persistent facial erythema of rosacea; approval was based on clinically significant efficacy and good safety data from large-scale clinical trials. Use of brimonidine in routine clinical practice has yielded new insights that elaborate on the findings from clinical trials. For example, real-world use has shown that a percentage of patients (in our experience, approximately 10 to 20%) treated with brimonidine experience a worsening of erythema that has been called "rebound." Our routine use of this agent for >1 year has yielded strategies to set patient expectations, optimize treatment initiation, and minimize potential problems; this article details those strategies. Because we believe that the term "rebound" has been used to describe several physiologically distinct events, we have also proposed more specific terminology for such events. SN - 1545-9616 UR - https://www.unboundmedicine.com/medline/citation/25607906/Optimizing_the_use_of_topical_brimonidine_in_rosacea_management:_panel_recommendations_ DB - PRIME DP - Unbound Medicine ER -